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Abstract
Novel diagnostics for uterine cancer are urgently needed to reduce the burden of
invasive testing for the majority of healthy women with postmenopausal bleeding.
We have previously shown that uterine cancer cells can be detected by cytology in
urine and vaginal samples with high diagnostic accuracy. Here, we demonstrate its
potential to distinguish malignant cells of different aetiologies in the same urogenital
biofluid sample according to their distinctive morphology and immunoprofiles.
Synchronous tumours of the urogenital tract are uncommon but can cause diagnostic
confusion, delays and poor outcomes. A 79-year-old woman presented to accident
and emergency with postmenopausal bleeding. Voided urine and Delphi screener-
collected vaginal samples were assessed by cytology and immunocytochemistry. Two
malignant cell populations with distinct morphology and immunophenotypes
consistent with synchronous uterine and urothelial tumours were identified.
Subsequent routine diagnostics confirmed concurrent uterine carcinosarcoma and
high-grade urothelial carcinoma of the bladder. This case demonstrates that
cytology and adjunctive immunocytochemistry can simultaneously identify and
phenotype cancers of different aetiologies from a single urogenital biofluid
sample. This can help rationalise diagnostic pathways in complex, unusual cases of
dual urogenital primaries.
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1 | INTRODUCTION
Uterine cancer is the most common gynaecological malignancy in
high-income countries.1 Incidence rates are rising as a consequence of
the obesity epidemic, an ageing population and non-surgical treat-
ments for benign gynaecological disease.2 Most women with uterine
cancer present with postmenopausal bleeding, triggering sequential
investigation by transvaginal ultrasound, hysteroscopy and endome-
trial biopsy. These tests provoke anxiety, can be unpleasant, painful
and hazardous, and constitute an inefficient use of resource
given that only 5%–10% women with postmenopausal women
have sinister underlying pathology.3 Considerable research effort is
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therefore underway to develop a simple rule in/rule out test to
efficiently triage high-risk women for diagnostic work up whilst low-
risk women are safely reassured.4
We have previously shown that naturally shed uterine cancer cells
can be identified by cytology in urine and vaginal samples with high
diagnostic accuracy.5 Typical cytological appearances enable confident
classification by morphology alone but atypical appearances or mixed
populations of malignant cells can be distinguished by adjunctive
immunocytochemistry, since malignant cells maintain immunoprofiles
consistent with their site of origin. Here we describe the identification
and classification of two different malignant cell populations in urine
and vaginal fluid from a woman subsequently diagnosed with synchro-
nous uterine and bladder tumours.
2 | CASE REPORT
A 79-year-old woman presented to the Emergency Room with heavy
postmenopausal bleeding. She was visually impaired from glaucoma
and had a history of breast cancer. She lived with her son, who pro-
vided support with her activities of daily living. On examination, she
was moderately frail with a clinical frailty score of 6. She mobilised
with a zimmer frame. Vaginal examination revealed moderately heavy
vaginal bleeding, a normal vulva and vagina, and a large, firm pelvi-
abdominal mass. She was hemodynamically stable but with ongoing
bleeding and a haemoglobin level of 114 g/L. She was therefore
admitted to the gynaecology ward for tranexamic acid and further
investigations.
The patient was recruited to the developing tests for endometrial
cancer detection (DETECT) study,5 a prospective observational study
of urine and vaginal cytology for the detection of endometrial cancer
in women with postmenopausal bleeding. Study participation involved
the provision of a urine sample self-collected in a sterile pot and a
F IGURE 1 Delphi screener. The Delphi screener (Rovers Medical
Devices) is a vaginal fluid collection device designed for self-sampling
F IGURE 2 Microphotographs of voided urine sample. Single malignant high-grade urothelial carcinoma cells (green circle) and clusters of
adenocarcinoma cells (red arrowhead). (A) Papanicolaou slide section stained with haematoxylin & eosin 600; (B) Agar cell block section stained
with haematoxylin & eosin 400; (C) Immunocytochemistry for GATA3 using agar cell block section 400; and (D) Immunocytochemistry for
PAX8 using agar cell block section 400
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vaginal sample collected with a Delphi screener (Rovers Medical
Devices), prior to routine investigations for postmenopausal bleeding.
A member of the research team collected the vaginal sample with the
patient in the supine position, legs bent at the knee and abducted at
the hips. The Delphi screener (Figure 1) was inserted into the poste-
rior fornix of the vagina and 3 ml saline expelled from the reservoir
by depressing the plunger for 3 s. The fluid was then re-aspirated
by releasing the plunger whilst slowly withdrawing and rotating
the device. A sterile pot at the introitus collected residual fluid. The
process was repeated twice by re-filling the reservoir with saline and
re-aspirations performed until clear fluid was obtained.
The urine sample was positive for blood, protein, ketones and biliru-
bin by dipstick (blood-3+, protein-2+, ketones-2+, bilirubin-1+). Both
urine and vaginal samples were fixed immediately after acquisition with
equal volumes of BD CytoRich™ Red Preservative (CRR) (Becton,
Dickinson and Company), labelled with a unique study identifier and
transported to the Manchester Cytology Centre. Here, they were
centrifuged at 3000 RPM for 5 min, supernatant decanted and the pellet
re-suspended in 6 ml CRR for an hour to complete fixation. Further
centrifugation was carried out at 1500 RPM for 10 min, the supernatant
decanted and the remaining pellets prepared into liquid based cytology
(LBC) Papanicolaou stained slides using the BD Prepstain (Becton,
Dickinson and Company). The paired urine and vaginal Pap slides were
then screened and reported independently by a consultant Biomedical
Scientist and two consultant cytopathologists.
Both urine and vaginal cytology preparations contained two
morphologically distinct populations of malignant epithelial cells. The
first population comprised single cells with a small rim of cytoplasm
F IGURE 3 Microphotographs of vaginal sample. Single malignant high-grade urothelial carcinoma cells (green circle) and clusters of
adenocarcinoma cells (red arrowhead). All images at 400 magnification. (A) Papanicolaou slide section stained with haematoxylin & eosin;
(B) Agar cell block section stained with haematoxylin & eosin; (C) Immunocytochemistry for GATA3 using agar cell block section; and
(D) Immunocytochemistry for PAX8 using agar cell block section
TABLE 1 List of antibodies and
dilutions used for immunocytochemical
analysis
Antibody Clone Dilution Malignant urothelial cells Adenocarcinoma cells
CK7 OV-TL 12/30 1:250 Positive Positive
CK20 KS20.8 1:100 Positive Negative
GATA3 L50-823 1:100 Positive Negative
PAX 8 Polyclonal 1:200 Negative Positive
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and enlarged, angular, hyperchromatic nuclei containing coarse chro-
matin pattern and irregular nuclear outlines that were interpreted as
being high-grade urothelial carcinoma cells (Figures 2A and 3A). The
second population comprised 3-dimensional cell clusters with enlarged,
eccentric nuclei containing coarse granular chromatin pattern and
prominent nucleoli, which were interpreted as adenocarcinoma cells
with high-grade cytologic atypia, most likely of endometrial origin
(Figures 2A and 3A). The urine sample contained more high-grade
F IGURE 4 Magnetic resonance imaging scan of pelvis. Sagittal (A) and axial (B) T2 weighted sequences through the pelvis showing a large,
heterogeneous, solid mass distending the endometrial cavity (thin arrow) and a small synchronous lesion within the minimally distended urinary
bladder (block arrow). Sagittal T1 weighted sequence acquired 5 min post intravenous Gadolinium administration (C) shows heterogeneous
progressive enhancement of the endometrial mass with areas of hyperenhancement (thin arrow) anteriorly and non-enhancement/necrosis
centrally (short thin arrow). Small enhancing urinary bladder lesion again demonstrated (block arrow)
F IGURE 5 Microphotographs of uterine and bladder pathology. Haematoxylin & eosin-stained sections. Uterine carcinosarcoma shows
(A) high grade adenocarcinoma 200 and (B) sarcomatous elements 200; (C) Bladder biopsy shows high-grade urothelial carcinoma 200 and
(D) carcinoma-in-situ 100
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urothelial carcinoma cells and fewer adenocarcinoma clusters, whilst
the reverse was true for the vaginal sample.
Agar cell blocks were prepared for each sample by concentrating
residual material and embedding pellets into 3% molten agar with sub-
sequent preparation of haematoxylin and eosin (H&E) sections
(Figures 2B and 3B). A panel of immunocytochemistry (IHC) (Table 1)
was performed on the Ventana BenchMark ULTRA (Roche Diagnos-
tics) according to the manufacturer's instructions. The single malignant
cells interpreted as high-grade urothelial carcinoma stained positively
for GATA3 but negatively for PAX8 indicating urothelial origin
(Figures 2C and 3C), whilst the adenocarcinoma clusters stained posi-
tively for PAX8 but negatively for GATA3 indicating female genital
tract origin (Figures 2D and 3D). A cytological research diagnosis was
made of synchronous malignancies of the urothelial and female genital
tracts, most likely of endometrial origin, within 48 h of the patient's
admission to hospital.
Routine investigations included transvaginal and transabdominal
ultrasound scans, which showed an enlarged uterus, thickened endo-
metrium and a large endometrial mass that demonstrated increased
vascularity. Endometrial sampling by suction aspiration with a pipelle
endometrial sampler was attempted on the gynaecology ward, but the
procedure was poorly tolerated and abandoned. A subsequent hyster-
oscopy under general anaesthetic was suspicious for malignant dis-
ease and an endometrial biopsy yielded multiple fragments of
p53-abnormal atypical glandular epithelium with crowded, highly
complex glands demonstrating a cribriform architecture and marked
cytological atypia. The stroma contained highly pleomorphic malignant
cells. The overall appearances were consistent with carcinosarcoma of
female genital tract origin. A subsequent magnetic resonance imaging
(MRI) scan demonstrated a large heterogeneous endometrial mass
with prompt arterial enhancement and restricted diffusion, and a small
enhancing mucosal lesion within the right lateral wall of the urinary
bladder (Figure 4). A staging chest, abdominal and pelvic computerised
tomography (CT) scan showed enlarged pelvic and aortocaval lymph
nodes and a 2.6 cm lesion within the posterior aspect of the left
femur, suspicious for metastatic disease. The patient underwent total
abdominal hysterectomy, bilateral salpingo-oophorectomy and bilat-
eral pelvic lymph node sampling. Histology confirmed endometrial car-
cinosarcoma with involvement of the cervix, parametrium, both
fallopian tubes and ovaries, and metastatic spread to 3 of 8 right and
2 of 7 left pelvic lymph nodes (Figure 5A,B). The ultrasound guided
biopsy of the femoral lesion obtained necrotic, non-diagnostic tissue.
Her case was discussed at the Gynaecology Multidisciplinary Team
meeting and a diagnosis of at least FIGO 2009 Stage 3C1 uterine car-
cinosarcoma was made.
Further investigation of the urinary bladder lesion included
attempted outpatient flexible cystoscopy, which was cancelled on
first attempt pre-hysterectomy, due to a concurrent urinary tract
infection, and on second attempt post-hysterectomy, because it
was poorly tolerated. A cystoscopy was subsequently performed
under general anaesthetic and found a 1–2 cm carpet-like lesion
affecting the right lateral wall and base of the bladder. A directed
biopsy obtained fragments of bladder mucosa showing a high-grade
urothelial carcinoma (G3pTa) and carcinoma-in-situ (Figure 5C,D).
Further active treatment for either cancer was abandoned because
the patient developed vaginal and pulmonary recurrence shortly
after her hysterectomy. A clinical decision was made in partnership
with the patient and her family to pursue best supportive care, and
she sadly died 3 months later.
3 | DISCUSSION/CONCLUSION
We have previously shown proof-of-principle that endometrial cancer
can be detected in urine and vaginal samples by cytology.5 Here we
show that cytology and adjunctive immunocytochemistry can identify
synchronous cancers of different urogenital aetiologies in the same
biofluid sample. Whilst synchronous cancers of the urogenital tract
are uncommon, they can cause diagnostic confusion, treatment delays
and poor outcomes. Here we demonstrate that the distinctive mor-
phology and immunoprofiles of tumours originating from different
anatomical sites can be identified from a single biofluid sample by
cytology. This can help rationalise subsequent diagnostic pathways,
facilitate treatment planning and ensure that healthcare resources are
spent appropriately. Rapid cancer diagnosis is an important goal for
public sector healthcare providers since it improves efficiency and
reduces costs.6 It is also important for patients because early diagno-
sis of cancer is associated with less treatment-related morbidity,
improved survival outcomes and better long-term quality of life.7
Here, urine and vaginal cytology was conducted within the
confines of a research study, but their use in routine clinical prac-
tice could offer significant advantage. Non-invasive sampling com-
bined with the established discipline of cytopathology provides an
opportunity for a simple, community-based triage tool that rapidly
distinguishes benign from malignant causes of urogenital bleeding.
Women with positive urogenital cytology could be referred
urgently for invasive diagnostic work-up, whilst those with nega-
tive results could be safely reassured. This would ensure that
scarce healthcare resources are directed towards those with cancer
and healthy women are spared the burden of tests they ultimately
do not need. In an era of personalised medicine, the ‘one-size-fits-
all’ approach to diagnosis is outdated and needs urgent reform.
Diagnostics for uterine cancer have benefitted little from innova-
tion over the past 50 years, with women being exposed to tests
that lack specificity (transvaginal ultrasound scan) or are unaccept-
ably invasive (hysteroscopy, endometrial biopsy).4 The James Lind
Alliance Womb Cancer Priority Setting Partnership recognised this
unmet clinical need, finding “which women with abnormal vaginal
bleeding should be referred urgently for investigations?” to be the
second most important endometrial cancer research priority
according to patients, their carers, healthcare professionals and
members of the public.8 The importance of finding new solutions
to cancer diagnosis was also highlighted by “what simple, non-
invasive, painless, cost-effective, and convenient tests can be used
to detect cancer early” being ranked the most important research
priority in a similar gap analysis for Detecting Cancer Early.9
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Three previous case reports have demonstrated the potential for
urogenital cytology to inform uterine cancer diagnosis,10–12 and its
use is well established for the diagnosis, surveillance and monitoring
of bladder cancer patients.13,14 The identification of cancer cells in
these easily-obtained biofluids emphasises their potential as so-called
‘liquid biopsies’ and associated proteomic, genomic or metabolomic
biomarkers could facilitate high-throughput automated testing for
cancer early detection.15 Future developments, including single cell
technology, digital pathology platforms and machine learning algo-
rithms are on the horizon. These digital solutions may be trained to
recognise malignant cells by morphology, and when combined with
adjunctive immunocytochemistry, may pinpoint site(s) of origin.16 The
utility of urogenital cytology as a screening tool for asymptomatic
patients is untested but could provide the opportunity for home-
based self-sampling for high risk patients, for example in Lynch syn-
drome, who may be at increased risk of both endometrial and
urothelial tumours, and further research is needed.
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